An Economic Evaluation of Percutaneous Left Atrial Appendage Occlusion: Dabigatran and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Atrial Fibrillation Wednesday, May 29th, 2013

CIRCULATIONAHA: May 22, 2013

Background—Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with non-valvular atrial fibrillation (NVAF). However, the cost effectiveness of LAA occlusion compared to dabigatran and warfarin in patients with NVAF is unknown.

Methods and Results—Cost-utility analysis using a patient level Markov micro-simulation decision analytic model with a lifetime horizon was undertaken to determine the lifetime costs, quality-adjusted life years (QALY), and the incremental cost-effectiveness ratio (ICER) of LAA occlusion in relation to dabigatran and warfarin in patients with NVAF at risk for stroke without contraindications to oral anticoagulation (OAC).  Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.